title: Liposome-encapsulated doxorubicin (Doxil) and doxorubicin in the treatment of vaccine-associated sarcoma in cats.
abstract: The purpose of this randomized, multicenter study was to evaluate the toxicity and efficacy of liposome-encapsulated doxorubicin (LED) and doxorubicin (DOX) in the treatment of feline vaccine-associated sarcoma (VAS). Cats were divided according to their disease status into a microscopic arm (no evidence of gross disease) and a macroscopic arm (evidence of gross disease). Each arm was randomized to receive either LED (1-1.5 mg/kg i.v. q3 weeks) or DOX (1 mg/kg i.v. q3 weeks). Thirty-three cats were entered in the macroscopic arm of the study with an overall response rate of 39% (5 complete response and 8 partial response) and a median time to progression of 84 days. Response rates were not different between LED and DOX. Seventy-five cats were entered into the microscopic arm. When compared to a similar historical control population treated with surgery alone, the cats receiving chemotherapy had a prolonged median disease-free interval (388 days versus 93 days). No difference in efficacy was detected between LED and DOX. LED at 1.5 mg/kg induced delayed nephrotoxicosis in 23%, necessitating a decrease in the recommended dosage to 1 mg/kg, and cutaneous toxicosis in 21.7% of treated cats. This study showed that both DOX and LED are efficacious in the treatment of VAS and should be considered in the treatment of this tumor.
authors.affiliation: Department of Medical Sciences, University of Wisconsin-Madison, School of Veterinary Medicine, Madison, WI 53706, USA.
authors.forename: Valerie J
authors.initials: VJ
authors.lastname: Poirier
authors.forename: Douglas H
authors.initials: DH
authors.lastname: Thamm
authors.forename: Ilene D
authors.initials: ID
authors.lastname: Kurzman
authors.forename: K Ann
authors.initials: KA
authors.lastname: Jeglum
authors.forename: Ruthanne
authors.initials: R
authors.lastname: Chun
authors.forename: Joyce E
authors.initials: JE
authors.lastname: Obradovich
authors.forename: Maura
authors.initials: M
authors.lastname: O'Brien
authors.forename: Rogers M
authors.initials: RM
authors.lastname: Fred
authors.forename: Brenda S
authors.initials: BS
authors.lastname: Phillips
authors.forename: David M
authors.initials: DM
authors.lastname: Vail
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D002371:Cat Diseases / Q000188:drug therapy* / Q000209:etiology; D002415:Cats; D004317:Doxorubicin / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D008081:Liposomes; D008297:Male; D012509:Sarcoma / Q000188:drug therapy* / Q000209:etiology / Q000662:veterinary*; D012983:Soft Tissue Neoplasms / Q000188:drug therapy* / Q000209:etiology / Q000662:veterinary*; D016896:Treatment Outcome; D014611:Vaccination / Q000009:adverse effects* / Q000662:veterinary*
chemical_list: D000970:Antineoplastic Agents; D008081:Liposomes; D004317:Doxorubicin